Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
What this study found
No significant change in oxidative/anti-oxidative status or liver enzymes with resveratrol vs placebo after 12 weeks. MDA, ox-LDL, TAC, SOD, GSH-Px, ALT, AST, GGT, and ALP showed no significant differences (P>0.05). BMI decreased modestly with resveratrol versus placebo (mean difference ≈ -0.31 kg/m2; 95% CI -0.64 to -0.02; P<0.05). Conclusion: 600 mg/day resveratrol for 12 weeks does not improve oxidative/anti-oxidative status in NAFLD; any observed BMI reduction is small and does not support antioxidant benefits at this regimen.
- Study & population
- 60 NAFLD patients (aged 20-60 years; BMI 25-35 kg/m2; 41 males, 19 females) diagnosed by liver ultrasonography; randomized, double-blind, placebo-controlled clinical trial.
- Intervention
- 600 mg resveratrol daily (two 300 mg capsules of pure trans-resveratrol) for 12 weeks; oral administration.
- Key limitation
- Ultrasound-based diagnosis of NAFLD; single-center study; relatively small sample with 9 dropouts (60 randomized, 51 completed); short duration (12 weeks); participants largely metabolically healthy at baseline (liver enzymes normal), which may limit responsiveness; results may not generalize to other doses or…
View source
Open PDFOriginal abstract
Purpose: Despite a proposed role for oxidative stress in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), antioxidant approaches have not been sufficiently investigated in human NAFLD management. Resveratrol has been reported to possess a wide range of biological functions, including antioxidant activities. This study aimed to evaluate the effects of resveratrol supplementation on oxidative/anti-oxidative status in patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted on 60 patients with NAFLD (males and females) aged 20 to 60 years, and body mass index (BMI) of 25-35 kg/m2. Subjects were randomly assigned to receive a daily dose of 600 mg resveratrol (2×300 mg pure trans-resveratrol capsules; n=30) or placebo capsules (n=30) for 12 wk. Fasting blood samples, anthropometric measurements, and dietary intakes were collected for all patients at baseline and at the end of the trial. Oxidative stress was evaluated by measurement of serum malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), total antioxidant capacity (TAC), and erythrocyte superoxide dismutase (SOD) as well as glutathione peroxidase (GSH-Px) activities. Changes in the outcomes were analyzed using analysis of covariance (ANCOVA). Results: Resveratrol supplementation did not significantly affect neither serum MDA, ox-LDL, and TAC levels, nor erythrocyte SOD and GSH-Px activities, compared to placebo group (All P>0.05). Moreover, changes in serum levels of liver enzymes (ALT, AST, GGT, and ALP) were not significant in neither of the study groups (All P>0.05). Conclusion: Resveratrol supplementation did not modify oxidative/anti-oxidative status in patients with NAFLD.